Core Viewpoint - Prenetics Global Limited has announced an update to its voluntary warrant exchange program, which aims to reduce potential dilution and simplify its capital structure [1][6]. Participation and Impact - In the October 2025 financing round, 2,722,642 Class A ordinary shares were issued, resulting in a total of 5,445,284 warrants (one Class A and one Class B warrant for each share) [2]. - As of the announcement date, 4,720,832 of the total warrants have been covered by exchange agreements, indicating approximately 86.7% participation, an increase from 83.4% [3]. - The exchange is expected to result in approximately 2.36 million Class C warrants being issued in exchange for the Class A and Class B warrants [4]. Warrant Exchange Details - Post-exchange, the total number of outstanding warrants (Class A, Class B, and Class C) is projected to be around 3.08 million, reflecting a reduction of approximately 43.3% from the original Class A and Class B warrants issued [5]. - The dilutive impact of the new warrants on the total outstanding shares is estimated to be about 18.3%, down from 32.3% [5]. Strategic Benefits - The company believes that the increased participation in the warrant exchange will enhance the investability of its ordinary shares and simplify its capital structure [6]. Warrant Exchange Terms - The exchange agreements stipulate that the company can exercise its forced-redemption right only after the registration statement on Form F-3 is effective and if the Class A ordinary shares trade at or above 120% of the exercise price ($21.60) for ten consecutive trading days [7]. - All eligible warrant holders were offered identical terms for participation in the exchange [8]. Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved over $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplement industry [9].

Core Insights - Prenetics Global Limited has strategically realigned its focus exclusively on its consumer health brand IM8, ceasing all Bitcoin acquisition activities to capitalize on IM8's growth potential [1][4][5] - IM8 has achieved remarkable success, becoming the fastest-growing supplement brand in history, with over $100 million in annualized recurring revenue (ARR) within just 11 months of its launch [2][6] - The company maintains a strong financial position with over $70 million in cash, 510 BTC as a treasury reserve, and no debt, providing a solid foundation for the expansion of IM8 [3][4] Company Strategy - The decision to focus solely on IM8 is aimed at maximizing long-term shareholder value and reflects the company's commitment to disciplined governance and strategic clarity [5][3] - Capital allocation will be directed exclusively towards the growth and operations of IM8, including product innovation, brand building, talent acquisition, working capital, and international expansion [4][5] Product Overview - IM8 is positioned as a premium core nutrition brand, co-founded by David Beckham, and combines advanced science with natural ingredients to promote health and longevity [6][7] - The flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements in a single drink and is certified for sport, non-GMO, vegan, and free from common allergens [7]

Core Viewpoint - Prenetics Global Limited has initiated a warrant exchange program to simplify its capital structure and reduce potential future dilution, with approximately 83.4% of outstanding Class A and Class B warrants participating in the exchange [1][2][3] Warrant Exchange Program - The program was developed based on feedback from institutional shareholders who supported consolidating legacy warrants into a cleaner structure [2] - The exchange agreements cover 4,539,722 of the 5,445,284 total Class A and Class B warrants, representing approximately 83.4% participation [3] Summary of the Warrant Exchange - The Company can exercise its forced-redemption right only after the registration statement for Class C warrants is effective and if Class A shares trade at or above $21.60 for ten consecutive trading days [4] - All eligible warrant holders were offered identical terms for participation in the exchange [5] Impact on Capital Structure - Approximately 4.54 million Class A and Class B warrants are expected to be exchanged for about 2.27 million Class C warrants [6] - Post-exchange, the total number of outstanding warrants is expected to be around 3.18 million, a reduction of approximately 42.0% from the original issuance in October 2025, with potential for up to 50% reduction if all holders participate [7] Strategic Rationale and Benefits - The exchange offers several benefits, including the consolidation of two legacy warrant classes into one Class C warrant with a lower exercise price of $18.00 and a two-year term [9] - Participation from the largest institutional investors indicates strong confidence in the revised structure and its long-term benefits [10] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its IM8 brand achieving over $100 million in annual recurring revenue within 11 months of launch [11] - IM8 combines advanced science with natural ingredients to provide a holistic approach to health, featuring products like Daily Ultimate Essentials [12]

Prenetics Global Conference Summary Company Overview - **Company**: Prenetics Global (Ticker: PRE) - **Industry**: Consumer Healthcare, specifically in dietary supplements and diagnostics - **CEO**: Danny Young, co-founder since 2014 Key Points and Arguments Company Background and Growth - Prenetics started as a life sciences diagnostics testing company and pivoted to PCR testing during COVID, conducting over 28 million tests and generating $800 million in revenue over three years [2][3] - The company went public on NASDAQ in 2022 and is now positioned as the world's fastest-growing consumer healthcare brand [2] - Projected revenues for 2025 are approximately $90-$100 million, with expectations to reach $180-$200 million in 2026 driven by the IM8 brand [2][3] IM8 Brand - IM8 is a premium supplement brand co-founded with David Beckham, focusing on a scientific approach to health supplements [5][6] - The brand achieved $100 million in annual recurring revenue (ARR) within 11 months of launch, a record in the supplement industry [7][8] - Monthly revenue grew from $600,000 to $10 million over the past year, indicating strong growth momentum [8] - IM8 products are designed to simplify supplementation, offering multiple nutrients in a single powdered drink [10][11] Financial Metrics - The company has a strong balance sheet with approximately $70 million in cash and $117 million in total assets, including Bitcoin holdings [3][14] - The IM8 business is valued conservatively at $380 million, with a projected ARR run rate of $120 million [3][15] - The average order value increased from $110 to $145 after launching a new product, Daily Ultimate Longevity, indicating strong consumer demand [19] Market Position and Strategy - Prenetics operates in 41 countries, with a direct-to-consumer model that allows for better customer data utilization and marketing strategies [9][23] - The company plans to focus on two to three new product launches annually, maintaining a streamlined product line [18][19] - The management team emphasizes transparency and quality, with all products being NSF Certified for Sport and third-party tested [20] Divestment Strategy - Prenetics is divesting from legacy business units (Europa, CircleDNA, Insighta) to focus on the growth of IM8 [4][28][29] - The divestment of Insighta, valued at $70 million, is aimed at reallocating resources to enhance shareholder value [29] Bitcoin Strategy - The company initiated a Bitcoin treasury strategy to hedge against inflation, purchasing Bitcoin daily while maintaining a significant cash reserve [25][26] - The Bitcoin to cash ratio is expected to be around 30%-35%, ensuring operational liquidity [26] Competitive Landscape - Prenetics is positioned uniquely in the $700 billion global supplement market, with a focus on high-quality, scientifically-backed products [17][30] - The company believes it is undervalued in the market, trading at or slightly above cash and asset value, presenting a significant investment opportunity [30][31] Additional Insights - The company has received over 10,000 five-star reviews in just 11 months, indicating strong customer satisfaction [12] - High-profile endorsements from athletes like Aryna Sabalenka enhance brand visibility and credibility [12][21] - The management team has extensive experience in scaling businesses, which is crucial for navigating the competitive landscape [30] This summary encapsulates the key insights from the Prenetics Global conference, highlighting the company's growth trajectory, strategic focus, and market positioning.

Core Insights - Prenetics Global Limited is actively participating in upcoming investor conferences, showcasing its commitment to investor engagement and transparency [2][3]. Group 1: Investor Conferences - The company will attend The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025, where CEO Danny Yeung will hold one-on-one meetings with investors [2]. - Prenetics will also participate in Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, with a formal presentation by CEO Danny Yeung on December 10 at 10:00 a.m. Eastern Time, followed by one-on-one meetings with CFO Stephen Lo [3]. Group 2: Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved $108 million in Annual Recurring Revenue (ARR) within 12 months of launch, marking the fastest growth in the supplement industry [5]. - The company has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 501 BTC as of November 24, 2025, indicating its innovative approach at the intersection of health and digital assets [6]. Group 3: IM8 Brand - IM8, co-founded with David Beckham, offers a premium core nutrition product, Daily Ultimate Essentials, which replaces 16 different supplements in a single drink and is NSF Certified for Sport, non-GMO, and vegan [7].

Core Insights - Prenetics Global Limited, a health-tech and longevity company, has announced that its executive leadership team has made open market purchases of the company's common stock, indicating strong internal confidence in the company's future [1][5]. Executive Purchases - The executive team collectively acquired 111,911 shares for approximately $1,446,887 [2]. - CEO Danny Yeung purchased 40,118 shares for about $502,000 at an average price of $12.51 per share [3]. - CMO Rahul Ramchand bought 60,000 shares for approximately $793,972 at an average price of $13.23 per share [4]. - CFO Stephen Lo acquired 8,000 shares for about $100,915 at an average price of $12.61 per share [4]. - President of Americas David Vanderveen purchased 3,793 shares for approximately $50,000 at an average price of $13.15 per share [5]. Company Overview - Prenetics is a leading health sciences company focused on redefining health and longevity through its flagship brand IM8, co-founded with David Beckham [6]. - IM8 has achieved $100 million in Annual Recurring Revenue within 11 months of launch, marking the fastest growth in the supplement industry [6]. - Prenetics is the first consumer health company to establish a Bitcoin treasury, currently holding 501 BTC, and purchases 1 Bitcoin daily [7]. Product Information - IM8 offers a premium core nutrition product, Daily Ultimate Essentials, which is an all-in-one powder supplement designed to replace 16 different supplements [8].

Core Insights - Cantor Fitzgerald has reiterated its Overweight rating on Prenetics Global Limited, adjusting the 12-month price target to $31 from $32, reflecting updates related to the planned divestment of its Europa business while maintaining a positive long-term outlook on the company [1][2] Financial Performance - Prenetics reported a 3Q25 revenue of $23.6 million, representing approximately 568% year-over-year growth, with IM8 revenue reaching $17.2 million, up about 76% sequentially and achieving gross margins of around 60% [5] - The company has a customer payback period of approximately 3.9 months and an 80%+ subscription rate, indicating strong unit economics [5] - As of November 10, 2025, Prenetics holds approximately 387 BTC valued at around $41 million, contributing to total liquidity of approximately $120 million [5] Market Position and Valuation - Cantor views Prenetics as undervalued, with PRE trading at just 0.7× EV/2026E revenue compared to approximately 1.1× for consumer-health peers [2] - Cantor forecasts FY2026 revenue of approximately $217 million, driven by continued momentum from IM8 and international expansion [5] Management Commentary - CEO Danny Yeung emphasized that Cantor's ongoing research coverage highlights Prenetics' emergence as a global leader in health and longevity, reinforcing investor understanding of the significant opportunities ahead as IM8 scales internationally [2]

Financial Data and Key Metrics Changes - Total revenue surged 568% year over year to $23.6 million in Q3 2025, driven by IMA's 76% quarter-to-quarter growth [9] - Adjusted EBITDA loss improved from $6.5 million in Q1 to $2.1 million in Q3, indicating operational leverage and a clear path to profitability [12][17] - Cash increased to approximately $82 million and Bitcoin holdings valued at around $40 million, resulting in total liquidity of about $120 million with zero debt [7][18] Business Line Data and Key Metrics Changes - IMA achieved $100 million annual recurring revenue (ARR) in the last 11 months, with projections to reach $300 million ARR by the end of 2026 [6] - Subscription rate for IMA stands at 80%, with an average order value increasing by 36% quarter over quarter to $150 [10][11] - Gross margin improved to 60% from 52%, reflecting enhanced profitability [10] Market Data and Key Metrics Changes - International markets now account for 56.5% of total revenue, with the U.S. being the top market followed by Canada, the U.K., Australia, and Singapore [10] - IMA has achieved over 420,000 customer purchases across 31 countries, indicating strong global demand [9] Company Strategy and Development Direction - The company aims to create a new category at the intersection of health and wealth, targeting $1 billion in annual revenue by 2030 [6] - A strategic divestment of non-core assets is underway to focus resources on IMA, the highest margin growth engine [14] - The company is leveraging partnerships with high-profile individuals to enhance brand visibility and credibility [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $180-$200 million in revenue for 2026, driven by international expansion and new product launches [18] - The company is strategically choosing to scale aggressively rather than prioritize short-term profitability, aiming to capture maximum market share [18] Other Important Information - The company has initiated a Bitcoin accumulation strategy, purchasing one Bitcoin daily since August 1, which is part of a sustainable framework to build shareholder value [8] - The recent $44 million funding round attracted notable investors, enhancing the company's financial position [6] Q&A Session Summary Question: Impressive payback period of 3.9 months - Management explained that the payback period has improved from four to five months at launch to 3.9 months now, indicating marketing efficiencies and strong unit economics [19][20] Question: Strong growth in international markets - Management noted that the U.S. market share has decreased from 70% to 46.5%, with significant growth observed in Canada, Europe, the Middle East, and Southeast Asia [21] Question: Need for additional capital for expansion - Management stated that with current liquidity, there is no expectation of needing new capital for expansion, emphasizing operational flexibility from recent fundraising [22][24]

Core Insights - Prenetics Global Limited has launched Daily Ultimate Longevity, a supplement targeting all 12 hallmarks of aging, reinforcing IM8's rapid growth in the supplement industry [1][3][4] - IM8 has achieved a compound annual growth rate of 2,457%, with monthly revenue increasing from approximately $600,000 to $6.6 million within nine months [1][4] - The global longevity market is projected to reach $314 billion by 2030, positioning IM8 at the forefront of this expanding market [7] Company Overview - Prenetics is a leading consumer health sciences company, with IM8 being one of the fastest-growing supplement brands co-founded by David Beckham [1][11] - The company maintains a strong financial foundation with over $90 million in liquid assets, including approximately $60 million in cash and 255.4 Bitcoin valued at around $31.6 million [10] Product Details - Daily Ultimate Longevity is formulated with IM8's proprietary 5-Complex System, delivering therapeutic doses of clinically-validated ingredients in a powder format [3][5][8] - The product is designed to target key aging pathways such as cellular senescence and mitochondrial dysfunction, supported by human clinical research [5][6][8] - It is priced at $149 for a one-time purchase and $119 per month for subscription, reflecting its premium positioning in the market [9] Market Positioning - The launch of Daily Ultimate Longevity is seen as a category-defining innovation in the rapidly growing longevity market [7][8] - The product's formulation includes high-dose glycine, taurine, and other key ingredients aimed at comprehensive cellular support and energy enhancement [8][12]

Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]